Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact
November 9, 2011
Circulating Tumor Cells as a Biomarker Approach in Oncology
Keynote Speaker for this Event:
  • Ken Pennline, PhD, Vice President and Global Head, Cytometry Services, LabCorp Clinical
      Learn More
  • Circulating Tumor Cells as a Biomarker Approach in Oncology

    Circulating tumor cells (CTCs) are rare in healthy individuals and patients with nonmalignant diseases, however, they are present in patients with various metastatic carcinomas. Some clinical studies indicate the number of CTCs present in the patient is an indicator of progression-free and overall survival for cancer patients. Therefore, evaluating CTCs can assist physicians to monitor and predict cancer progression for those with metastatic cancer.

    Key Takeaway Points:

    • CTCs as prognostic and predictive tools
    • Obtain extensive biomarker data without invasive procedures
    • Personalized therapy based upon CTC molecular pathology

    Pharma clinical and outsourcing teams focused on oncology and biomarkers


    Ken Pennline, PhD
    Vice President and Global Head, Cytometry Services
    LabCorp Clinical Trials

    Dr. Pennline, currently Vice President and Global Head, Cytometry Services for LabCorp Clinical Trials, received his Ph.D. in immunology from The Ohio State University in 1977. Previously he has held positions as a faculty member in the Department of Pathology and Director of the Immune Monitoring Laboratory at Georgetown University, Washington, DC, as Senior Principal Scientist and Director of Core Flow Cytometry at Schering Plough, Kenilworth, NJ, and as Global Director of Operations in Oncology/Cell Analysis for Esoterix Clinical Trial Services.


    LabCorp Clinical Trials, a division of LabCorp, combines standardized international laboratory capabilities with sophisticated diagnostic technologies to provide a broad portfolio of services and clinical assays to support drug and diagnostic clinical studies.

    • Full-service central laboratory support for Phase 1 through Phase IV studies
    • Dedicated clinical trials laboratories in Belgium, China, Singapore and the United States
    • Participation in more than 7300 clinical trials, including more than 1200 with international sites
    • Scientific leadership and innovation across major therapeutic areas
    • Comprehensive portfolio of clinical assays and laboratory services for accelerated drug development
    • Dedicated research and development services to assist in assay development and validation, and new assay implementation
    • Standardized test platforms and global reference intervals for real-time combined data
    • Global proficiency testing and quality control programs
    • Global courier and logistics solutions

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

    Copyright © 2016-2017 Honeycomb Worldwide Inc.